US 4,268,526 AGrant
Cosmetic Cream Formulation
Issue Date:1981-05-19
•1 Claims
Abstract
A skin cream formulation, which is one of four components used in a cosmetic regime, is disclosed. Applying the regime to the skin increases epidermal cell turnover without skin irritation. The other three components used in the regime are a cleanser, a lotion, and a tonic.
Metadata
Assignee
- Eli Lilly and Company
Inventors
- Ovidio Vargas
- Anne M. Herrold
Application Information
Application Number:US 1796267
Filing Date:1980-08-20
Priority Date:1980-08-20
Art Unit:125
Classifications
IPC:
A61K 702
Field of Search:
424273;358;365;184
Patent Drawings
This patent does not have any drawings.
Description
BACKGROUND OF THE INVENTION
This invention relates to one component for use in a novel cell renewal cosmetic regime, which regime increases the rate of cell turnover without skin irritation.
In the natural renewing cycle of skin, cells are constantly being born, rising through the epidermal layers to the surface and falling off. A young skin renews its surface layers every two to three weeks. A mature skin can take twice as long. And the longer this process takes, the more cells develop areas of weakness that cause a faster loss of natural moisture and the dry lifeless appearance that's found in older looking skin.
Acceleration of natural cell renewal or turnover speeds the replacement of dead cells by new ones in the outer epidermal layer or stratum corneum, thereby giving the skin a younger-looking appearance. The newer cells are moist and fresh, replacing the old, dry cells on the surface.
Although irritation of the skin will increase the sloughing off of dead stratum corneum cells, such irritation is undesirable because of the damage to the skin. It is, therefore, desirable to increase cell turnover without irritation.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide a skin cream formulation, which is one of four components for use in a cosmetic regime. The regime's use increases epidermal cell turnover without skin irritation. The other three components for use in the regime are: a cleanser, a lotion, and a tonic.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with this invention there is provided a skin cream formulation, which is one of four components for use in a cosmetic regime. The use of the regime increases cell turnover without causing skin irritation. The regime consists of the application to the skin of a cleanser, a cream, a lotion, and a tonic. Each of the three other components is a separate invention; the cleanser is claimed in application Ser. No. 179,628, filed of even date herewith, the lotion is claimed in application Ser. No. 179,629, also filed of even date herewith, and the tonic is claimed in application Ser. No. 179,625, filed of even date herewith. The use of the four components in a regime to increase cell turnover is claimed in application Ser. No. 179,627, filed of even date herewith.
The preferred regime usually begins in the morning with the use of the tonic, followed by the lotion. Later, usually at night, the cleanser is used, and then the tonic and cream are applied. However, the order and the timing of the use of the four products can be varied to suit individual needs. For example, the cleanser also can be used in the morning. Some effect will be obtained even if all the compositions are not used or if there is a delay between usage.
The cream formulation consists essentially of, in percent by weight:
In general, the individual ingredients used in the formulation should be of a quality or purity (such as U.S.P. or N.F.) suitable for cosmetic use.
The formulation of this invention is prepared by mixing the ingredients according to conventional methods. The preparation of this formulation is described in the following example. The example is illustrative of the formulation embraced by the invention, but is not to be construed as limiting the invention.
EXAMPLE 1
Cream
Formulation:
Procedure:
The light mineral oil of Phase A is heated to about 90.degree.-95.degree. C. and then the polyethylene is added while mixing with a Lightnin' mixer. The mixing is continued until Phase A becomes a clear solution. The ingredients of Phase B are added to a jacketed tank that is equipped with a homomixer and a side-sweep (Ross). Phase B is heated to about 90.degree.-95.degree. C. and mixed thoroughly. Phase A is added to Phase B and then mixed thoroughly with the homomixer.
While Phase AB is being mixed with the homomixer, the Bentone of Phase C is slowly sprinkled into Phase AB. Mixing is continued until the Bentone is completely wetted and a homogeneous mass is acquired. The temperature is maintained at 90.degree.-95.degree. C.
The ingredients of Phase D are added to a container equipped with a Lightnin' mixer. The container is then heated to about 90.degree.-95.degree. C. and Phase D is mixed until the powder ingredients are dissolved. Phase D is added to Phase ABC and mixed with the homomixer and side-sweep. The product is homomixed until it becomes homogeneous and has a bright white shine. Homomixing is stopped when the product has cooled to 50.degree. C., but side-sweeping continues. The product is then cooled, but must not be shock cooled.
Phase E is prepared separately by dissolving the Dowicil 200 in the deionized water. Phase ABCD is cooled to about 40.degree.-45.degree. C. and Phase E is added. The product is mixed thoroughly with the side-sweep. Phase F is added, keeping the mixture at about 40.degree.-45.degree. C. and mixing completely. The product is then discharged into suitable stainless steel storage containers.
When the above-described formulations are used in accordance with the method of this invention, the rate of skin cell turnover is increased without skin irritation. The rate of skin cell turnover is frequently reported as transit time. Transit time is defined as the time required for a newly formed stratum corneum cell to rise up through the stratum corneum and finally slough off. Therefore, the less transit time required, the better the appearance of the skin, because younger cells are on its surface.
The test for measuring transit time is described by L. H. Jansen, et al., "Improved Fluorescence Staining Technique for Estimating Turnover of the Human Stratum Corneum", British Journal of Dermatology, 1974, 90, 9-12. The transit or replacement time of the human stratum corneum is determined by measuring the number of days required for a fluorescent marker, dansyl chloride, to disappear after application to the skin. The dansyl chloride only stains the stratum corneum (outer cell layer) and the shedding of the stratum corneum is signified by the disappearance of the dansyl chloride.
Using the Jansen procedure, the transit time of the present regime is measured and compared with the transit time of several commercially available, skin-care cosmetic products, identified as products A to E in Table I. Dansyl chloride is applied to both upper inner arms of each subject, after two weeks of pretreatment with the product. Then one arm is treated daily with the particular product, while the other arm is untreated. The number of days required for the dansyl chloride to disappear from each arm is then recorded. The results for the treated arms are averaged for the particular product and compared to the average for the untreated arms. The results are shown in Table I. The larger the difference between the control and treated times, the more effective is the product.
The test was run using women from young (19-29 years) and middle (31-58 years) age groups for products A-E and the regime.
The present regime consists of using all four components in the following order: the cleanser and tonic were used in the morning, followed by the lotion; later, at night, the cleanser was used and then the tonic and cream were applied.
Claims
We claim:
1. A skin cream formulation consisting essentially of, in percent by weight: Ingredients Percent ______________________________________ light mineral oil 4.45 polyethylene homopolymer (1500 m. wt., density 0.91 g/cc) 2.50 undecanoic triglyceride 2.00 squalane 5.00 distilled lanolin alcohol 0.55 white beeswax 1.00 polydimethyl cyclosiloxane 9.00 triglyceryl diisostearate 4.00 isopropyl myristate 5.00 propyl p-hydroxybenzoate 0.10 quaternary bentonite 0.40 deionized water 59.00 methyl p-hydroxybenzoate 0.20 70% sorbitol solution 5.00 imidazolidinyl urea 0.30 urea 0.50 glyoxyldiureide 0.20 DL-pantothenyl alcohol 0.50 cis-1-(3-chloroallyl)-3,5,7-triaza-1- azoniaadamantane chloride 0.10 fragrance 0.20 ______________________________________
Non-Patent Literature (2)
- A-C Polyethylene Bulletin (5011-22-4) Jul. 14, 1977. _
- A-C Polyethylene Bulletin (5011-20-1) Jun. 21, 1977. _